ParkinsonFranceV1, Main, Exploration, bibRecord, 004A77

Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans

Identifieur interne : 004A77 ( Main/Exploration ); précédent : 004A76; suivant : 004A78

Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans

Auteurs : J. Dow [France] ; F. Piriou ; E. Wolf [France] ; B. D. Dulery [France] ; K. D. Haegele

Source :

Drug metabolism and disposition [ 0090-9556 ] ; 1994.

RBID : Pascal:94-0697054

Descripteurs français

Pascal (Inist)
- IMAO, Amine oxidase (flavin-containing), Pharmacocinétique, Métabolisme, Métabolite, Chien, Animal, Homme, Antiparkinsonien, Voie orale, Voie intrapéritonéale, Mofégiline.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Amine oxidase (flavin-containing), Animal, Antiparkinson agent, Dog, Human, Intraperitoneal administration, MAO inhibitor, Metabolism, Metabolite, Oral administration, Pharmacokinetics.

Abstract

Mofegiline or MDL 72,974A ((E)-4-fluoro-β-fluoromethylene benzene butanamine hydrochloride) is a selective enzyme-activated irreversible inhibitor of monoamine oxidase B, which is under development for use in the treatment of Parkinson's disease. Male beagle dogs were given single po (20 mg/kg) and iv (5 mg/kg) doses of [¹⁴C]-Mofegiline. Total radioactivity excreted in urine and feces over 96 hr was, respectively, 75.5±3.8 and 6.3±3.4% of the dose after po and 67.9±0.5 and 3.9±2.4% after iv administration. Unchanged drug in urine represented 3% of the dose after po and less than 1% after iv administration. Mofegiline was thus extensively metabolized in dogs, and urinary excretion was the major route of elimination of metabolites

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001935
to stream PascalFrancis, to step Curation: 001717
to stream PascalFrancis, to step Checkpoint: 001790
to stream Main, to step Merge: 005434
to stream Main, to step Curation: 004A77

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans</title>
<author><name sortKey="Dow, J" sort="Dow, J" uniqKey="Dow J" first="J." last="Dow">J. Dow</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Marion Merrell Dow, dep. drug metabolism</s1>
<s2>67080 Strasbourg</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Piriou, F" sort="Piriou, F" uniqKey="Piriou F" first="F." last="Piriou">F. Piriou</name>
</author>
<author><name sortKey="Wolf, E" sort="Wolf, E" uniqKey="Wolf E" first="E." last="Wolf">E. Wolf</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Marion Merrell Dow, dep. drug metabolism</s1>
<s2>67080 Strasbourg</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dulery, B D" sort="Dulery, B D" uniqKey="Dulery B" first="B. D." last="Dulery">B. D. Dulery</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Marion Merrell Dow, dep. drug metabolism</s1>
<s2>67080 Strasbourg</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haegele, K D" sort="Haegele, K D" uniqKey="Haegele K" first="K. D." last="Haegele">K. D. Haegele</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">94-0697054</idno>
<date when="1994">1994</date>
<idno type="stanalyst">PASCAL 94-0697054 INIST</idno>
<idno type="RBID">Pascal:94-0697054</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001935</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001717</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001790</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001790</idno>
<idno type="wicri:doubleKey">0090-9556:1994:Dow J:novel:carbamate:metabolites</idno>
<idno type="wicri:Area/Main/Merge">005434</idno>
<idno type="wicri:Area/Main/Curation">004A77</idno>
<idno type="wicri:Area/Main/Exploration">004A77</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans</title>
<author><name sortKey="Dow, J" sort="Dow, J" uniqKey="Dow J" first="J." last="Dow">J. Dow</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Marion Merrell Dow, dep. drug metabolism</s1>
<s2>67080 Strasbourg</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Piriou, F" sort="Piriou, F" uniqKey="Piriou F" first="F." last="Piriou">F. Piriou</name>
</author>
<author><name sortKey="Wolf, E" sort="Wolf, E" uniqKey="Wolf E" first="E." last="Wolf">E. Wolf</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Marion Merrell Dow, dep. drug metabolism</s1>
<s2>67080 Strasbourg</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dulery, B D" sort="Dulery, B D" uniqKey="Dulery B" first="B. D." last="Dulery">B. D. Dulery</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Marion Merrell Dow, dep. drug metabolism</s1>
<s2>67080 Strasbourg</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haegele, K D" sort="Haegele, K D" uniqKey="Haegele K" first="K. D." last="Haegele">K. D. Haegele</name>
</author>
</analytic>
<series><title level="j" type="main">Drug metabolism and disposition</title>
<title level="j" type="abbreviated">Drug metab. dispos.</title>
<idno type="ISSN">0090-9556</idno>
<imprint><date when="1994">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drug metabolism and disposition</title>
<title level="j" type="abbreviated">Drug metab. dispos.</title>
<idno type="ISSN">0090-9556</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amine oxidase (flavin-containing)</term>
<term>Animal</term>
<term>Antiparkinson agent</term>
<term>Dog</term>
<term>Human</term>
<term>Intraperitoneal administration</term>
<term>MAO inhibitor</term>
<term>Metabolism</term>
<term>Metabolite</term>
<term>Oral administration</term>
<term>Pharmacokinetics</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>IMAO</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Pharmacocinétique</term>
<term>Métabolisme</term>
<term>Métabolite</term>
<term>Chien</term>
<term>Animal</term>
<term>Homme</term>
<term>Antiparkinsonien</term>
<term>Voie orale</term>
<term>Voie intrapéritonéale</term>
<term>Mofégiline</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Mofegiline or MDL 72,974A ((E)-4-fluoro-β-fluoromethylene benzene butanamine hydrochloride) is a selective enzyme-activated irreversible inhibitor of monoamine oxidase B, which is under development for use in the treatment of Parkinson's disease. Male beagle dogs were given single po (20 mg/kg) and iv (5 mg/kg) doses of [<sup>14</sup>
C]-Mofegiline. Total radioactivity excreted in urine and feces over 96 hr was, respectively, 75.5±3.8 and 6.3±3.4% of the dose after po and 67.9±0.5 and 3.9±2.4% after iv administration. Unchanged drug in urine represented 3% of the dose after po and less than 1% after iv administration. Mofegiline was thus extensively metabolized in dogs, and urinary excretion was the major route of elimination of metabolites</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Alsace (région administrative)</li>
<li>Grand Est</li>
</region>
<settlement><li>Strasbourg</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Haegele, K D" sort="Haegele, K D" uniqKey="Haegele K" first="K. D." last="Haegele">K. D. Haegele</name>
<name sortKey="Piriou, F" sort="Piriou, F" uniqKey="Piriou F" first="F." last="Piriou">F. Piriou</name>
</noCountry>
<country name="France"><region name="Grand Est"><name sortKey="Dow, J" sort="Dow, J" uniqKey="Dow J" first="J." last="Dow">J. Dow</name>
</region>
<name sortKey="Dulery, B D" sort="Dulery, B D" uniqKey="Dulery B" first="B. D." last="Dulery">B. D. Dulery</name>
<name sortKey="Wolf, E" sort="Wolf, E" uniqKey="Wolf E" first="E." last="Wolf">E. Wolf</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A77 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A77 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:94-0697054
   |texte=   Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans

Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri